Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
04/17/2017 04/18/2017 04/19/2017 04/20/2017 04/21/2017 Date
55.4(c) 55.65(c) 56.95(c) 57.15(c) 55.9(c) Last
207 314 183 979 207 277 218 905 271 950 Volume
+0.73% +0.45% +2.34% +0.35% -2.19% Change
More quotes
Financials ($)
Sales 2017 536 M
EBIT 2017 140 M
Net income 2017 95,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 583 M
EBIT 2018 154 M
Net income 2018 103 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 19,75
P/E ratio 2018 18,21
Capi. / Sales2017 3,55x
Capi. / Sales2018 3,26x
Capitalization 1 900 M
More Financials
Company
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies to innovator and generic pharmaceutical companies.Its products include generic and branded APIs, controlled... 
Sector
Pharmaceuticals
Calendar
05/05Earnings Release
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
04/04 INSIDER TRADING ACTIVITY CAMBREX CO. : CBM) – CEO Sold 12,000 shares of St..
03/28 CAMBREX : Recognized At CMO Leadership Awards; Acknowledged as “Exceeding ..
03/23 GLOBAL NICOTINE GUM CONSUMPTION MARK : Reynolds American, Cambrex Corporation, F..
03/03 INSIDER TRADING ACTIVITY CAMBREX COR : CBM) – CEO Sold 12,000 shares of St..
02/28 INSIDER TRADING ACTIVITY CAMBREX COR : CBM) – COO Sold 19,620 shares of St..
02/15 Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conferen..
02/08 CAMBREX : riding high on demand for Western innovator APIs
02/03 CAMBREX CORPORATION : (CBM) Jumps on Earnings Estimate
02/03 CAMBREX : Management's Discussion and Analysis of Financial Condition and Result..
02/03 CAMBREX : posts 4Q profit
More news
Sector news : Pharmaceuticals - NEC
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
04/19DJFARON PHARMACEUTICALS OY : Appoints Two Non-Executive Directors
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/21Positive News Coverage Unlikely to Impact Cambrex $CBM Stock Price  
04/18Teachers Advisors LLC Sells 1,002 Shares of Cambrex Co. $CBM  
03/30Want automatic email alerts for $CBM $MAIL $ON $HTBX $CTR? Subscribe to Marke.. 
03/29#India gives #CBM producers a boost  
03/22Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Make.. 
More tweets
Qtime:14
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/07 CAMBREX : An Undervalued Stock
02/22 Cambrex (CBM) Presents at RBC Capital Markets Global Healthcare Conference 20..
02/15 CAMBREX : A Pure Growth Play
02/03 Cambrex's (CBM) CEO Steven Klosk on Q4 2016 Results - Earnings Call Transcrip..
Advertisement
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Full-screen chart
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 64,0 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Tom Vadaketh Chief Financial Officer & Vice President
Peter G. Tombros Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION5.93%1 900
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.88%200 330
NOVARTIS AG-1.15%192 857
MERCK & CO., INC.5.13%169 673
More Results